Telo Genomics Announces the Final Assignment of Patents on Hematological Cancers, Liquid Biopsy and Alzheimer’s Disease
11 Novembre 2020 - 6:26PM
Telo Genomics Corp. (TSX-V: TELO)
(the
“Company” or
“TELO”) is
pleased to announce that it has received final approval and grant
of three of its pending patent applications including:
- Diagnostic Methods for Hematological Disorders (Hematological
Cancers) - Canada
- Methods for Characterizing and isolating circulating tumor cell
subpopulations (Liquid biopsy) - Canada
- Methods of Diagnosing Alzheimer’s Disease - Europe
TELO has already been granted final patents
governing its intellectual property (“IP”) for hematological
cancers in the USA, and Alzheimer’s Disease in the USA and Canada.
TELO’s patent application on liquid biopsy in the USA is still
pending.
TELO has secured intellectual property
protection in various jurisdictions around the world and owns a
portfolio of patents and pending patent applications in the United
States, Canada and the EU. The scope of the IP covers its core
technology and specific applications of the technology. In addition
to the patents and pending patent applications, TeloView® is
protected as a trademark in the USA, Canada, Europe and Israel.
“The issuance of three additional final patents
further augments TELO’s already strong IP portfolio,” said Sabine
Mai, TELO Director, and Chair of the Clinical and Scientific
Advisory Board. “Blood cancers and liquid biopsy are at the core of
the Company’s commercialization program. The issuance of these
patents assures the long-term protection of the TeloView® platform
as a prognostic/diagnostic tool for these diseases.”
The Company would also like to announce that
pursuant to its press release dated October 21st, 2020, Leede Jones
Gable Inc. and Mackie Research Corp. have exercised 5,026,800 of
clients and broker warrants for gross proceeds of $944,180. As a
result, neither Leede nor Mackie will be soliciting further warrant
exercises going forward.
About Telo Genomics
Telo Genomics is a biotech company pioneering
the most comprehensive telomere platform in the industry with
powerful applications and prognostic solutions. These include
liquid biopsies and related technologies in oncology and
neurological diseases. Liquid biopsy is a rapidly growing field of
significant interest to the medical community for being less
invasive and more easily replicated than traditional diagnostic
approaches. By combining our team’s considerable expertise in
quantitative analysis of 3D telomeres with molecular biology and
artificial intelligence to recognize disease-associated genetic
instability, Telo Genomics is developing simple and accurate
products that improve day-to-day care for patients by serving the
needs of pathologists, clinicians, academic researchers and drug
developers. The benefits of our proprietary technology have been
substantiated in over 150 peer reviewed publications and in 25
clinical studies involving more than 3,000 patients with multiple
cancers and Alzheimer’s disease. Our lead application, Telo-MM is
being developed to provide important, actionable information to
medical professionals in the treatment of Multiple Myeloma, a
deadly form of blood cancer. For more information please visit
www.telodx.com.
For further information, please
contact:
Hugh
RogersDirector416-673-8487info@telodx.comMaRS Centre, South Tower,
101 College Street, Suite 200, Toronto, ON, M5G
1L7www.telodx.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as such term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding
Forward-Looking Statements
Certain information contained herein may
constitute “forward-looking information” under Canadian securities
legislation. Generally, forward-looking information can be
identified by the use of forward-looking terminology such as
“intends”, “will”, or variations of such words and phrases or
statements that certain actions, events or results “will” occur.
Forward-looking statements regarding the clinical efficacy of
products, commercial viability of products, use of proceeds, and
the ability of the TeloViewTM platform to deliver personalized
medicine resulting in better treatments and outcomes are based on
the Company’s estimates and are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information,
including capital expenditures and other costs. There can be no
assurance that such statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on forward- looking statements and
forward-looking information. The Company will not update any
forward-looking statements or forward-looking information that are
incorporated by reference herein, except as required by applicable
securities laws.
Telo Genomics (TSXV:TELO)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Telo Genomics (TSXV:TELO)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024